Loss of heterozygosity at 11p13 in Wilms' tumours does not necessarily involve mutations in the WT1 gene. by Cowell, J. K. et al.
Br. J. Cancer (1993), 67, 1259-1261 © Macmillan Press Ltd.,
Loss of heterozygosity at lipl3 in Wilms' tumours does not necessarily
involve mutations in the WT1 gene
J.K. Cowell, N. Groves & P. Baird
ICRF Oncology Group, Institute ofChild Health, 30 Guilford Street, London WCIN IEH, UK.
Summary Loss of heterozygosity (LOH) in tumour cells is generally accepted as 'exposing' recessive cancer
genes. The short arm of chromosome 11 shows consistent LOH in Wilms' tumours along its entire length.
Occasionally, however, only the lIpl3 and/or the lIpl5 regions are involved. Deletions of the Ip13 region
consistently predisposes to Wilms' tumorigenesis. We have analysed the recently cloned WTI gene from the
llpl3 region exon-by-exon in five tumours previously shown to have undergone LOH for the lipl3 region,
using single strand conformation polymorphism analysis (SSCP) and PCR sequencing. Our analysis using
SSCP failed to identify any band shifts in the WT1 gene from these tumours. In addition we also sequenced
the zinc finger region of WTI, which is the part of the gene most frequently showing mutations. Only the
normal sequence was found in all of these tumours. These results demonstrate that LOH in Wilms' tumours is
not always related to mutations in the WTI genes and argues strongly that another gene, probably in the
llp15 region, may be more important in Wilms' tumorigenesis.
In 1971, Knudson proposed his now-famous two hit hypo-
thesis, developed further by Comings (1973), stating that
both homologues of a single, critical gene must be inactivated
for tumour initiation. It is now generaly accepted that loss of
heterozygosity (LOH) is one means of 'exposing' the initial
recessive mutations in genes which, through their normal
action, prevent the development of tumours, hence their
name 'tumour suppressor genes'. This phenomenon was first
described by Cavenee et al. (1983) in retinoblastoma tumours
where the initial causative mutation was often duplicated at
the expense of the normal allele. The mechanisms by which
this was achieved included deletion, mitotic recombination
and chromosome non-disjunction although, in a proportion
of cases, the second mutation could be an independent muta-
tional event in another part of the gene (Dunn et al., 1989).
Since this observation many human hereditary cancers have
been shown to lose heterozygosity at the chromosomal locus
known to contain the predisposing gene (see Stanbridge, 1990
for review). The situation, however, is not so straightforward,
since in Wilms' tumour (WT), for example, where constitu-
tional deletions of chromosome region lip13 consistently
predispose to tumorigenesis, LOH is only seen in 30% of
tumours (Mannens et al., 1988; Wadey et al., 1990), com-
pared with 70% in Rb (Cavenee et al., 1983). It is also clear
that LOH in WT is not confined to region 1lp13 but often
extends into llplS and, in some tumours, LOH is restricted
to the 1 1p15 region (Wadey et al., 1990). This would suggest
that tumour suppressor genes are present in both lp13 and
1lpl5 which may act alone, or in concert, giving rise to
tumorigenesis. The 1lpl5 locus is believed to be the same
one which apparently predisposes to Beckwith-Wiedemann
syndrome (BWS), a complex malformative condition which
also predisposes to the development of WT and other
abdominal tumours (Wiedemann, 1983). Some cases of BWS
have been shown to carry constitutional reciprocal
chromosome translocations with one breakpoint in lp15
(Waziri et al., 1983) although it now appears that these
breakpoints may cluster in two separate regions (M. Man-
nens personal communication). Although little is known
about the Ipl5 gene(s) associated with Wilms' tumorigenesis
a gene from 1Ip13 was recently cloned (Call et al., 1990;
Gessler et al., 1990) which was termed WTI (Haber et al.,
1991). The WT1 gene contains 10 exons, the last four of
which code individually for four zinc finger motifs, involved
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in DNA binding (Call et al., 1990; Gessler et al., 1990). The
tissue-specific expression pattern of WTI (Call et al., 1990;
Pritchard-Jones & Fleming, 1991) supports its role in the
development of the kidney, as well as the genital system. In a
small percentage of patients with WT there is an association
with aniridia, genitourinary abnormalities and mental retar-
dation, the so-called AGR triad (Riccardi et al., 1978). These
patients frequently carry constitutional deletions of the short
arm of lIp always involving Ip13 (Narahara et al., 1984). It
has already been shown that the remaining WT1 allele in
these AGR patients is also mutated (Brown et al., 1992;
Baird et al., 1992a) implicating this gene in tumorigenesis.
The other tumours where it might be expected to find WT1
mutations is in those showing LOH at lIpl3. We recently
reported our analysis of a large series of Wilms' tumours
where LOH had been characterised (Wadey et al., 1990) and,
in this study, we have analysed the WTl gene sequence for
mutations in these tumours.
Materials and methods
For single strand conformational polymorphism (SSCP) ana-
lysis individual WT1 exons were amplified using the primers
and conditions described in detail by Baird et al. (1992b).
Amplified products varied in size between 120 and 255 bp
and as such are ideal for SSCP analysis without prior diges-
tion with restriction enzymes. Individual PCR products were
electrophoresed through 6% non-denaturing polyacrylamide
gels at 30 W in a cold (±4C) room for 6 h. The gels were
processed for autoradiography in the standard way (Hogg et
al., 1992) and exposed without intensifying screens for
24-48 h.
For the sequencing reaction one of the primers used was
biotinylated (Baird et al., 1992a) which allowed recovery of
the PCR product using magnetic strepavadin-coated beads
(Dynal, Merseyside) without contamination with the unincor-
porated primers. The non-biotinylated oligonucleotide was
then used to prime the sequencing reaction using the condi-
tions described in detail by Hogg et al. (1992).
Results and discussion
Of the tumours reported by Wadey et al. (1990) showing
LOH in lIp, three involved only the IIpS5 region. DNA was
only available from six of the remaining eight tumours which
showed LOH for Ip13 (Figure 1). We decided to investigate
whether mutations were present in the retained copy of the
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Figure 1 Summary of the extent of loss of heterozygosity in Wilms' tumours analysed for mutations. The closed circles indicate
LOH and the open circles represent areas of retention of heterozygosity. The hatched circles indicate that the patient was
homozygous at that locus.
in these six tumours, the histological subtype of which has
been presented in detail elsewhere where, in fact, there is
nothing remarkable to distinguish these tumours from those
which did not shown LOH for 'p markers (Wadey et al.,
1990). Our approach was to screen each individual exon of
WT1 using the single strand conformation polymorphism
(SSCP) technique and direct sequencing of the PCR-ampli-
fied products. We have recently shown that SSCP is an
efficient method for the detection of mutations in the RB1
gene (Hogg et al., 1992; Onadim et al., 1992b) and we have
extended these studies to the analysis of the WTI gene (Baird
et al., 1992a,b). Details of the primers used to amplify each
exon have been described by Baird et al. (1992b). The WTI
gene was amplified exon-by-exon with the exception of a
small (60 bp), highly GC-rich (Haber et al., 1991) region of
exon 1, which makes sequencing difficult to interpret.
One of the six tumours came from a patient with Denys-
Drash syndrome (GOS 217) which represents a distinct group
of Wilms' patients who carry constitutional mutations in
WT1 (Pelletier et al., 1991a). As such tumours from these
patients cannot be classified as truly sporadic and, indeed
patient GOS 217 was shown to have a constitutional muta-
tion in exon 6 (Baird et al., 1992a) which became homozy-
gous in the tumour. From the five sporadic tumours showing
LOH no band shifts were seen in the SSCP gels from any of
the exons. Previous Southern blot analysis of LOH in these
tumours (Wadey et al., 1990) showed only weak (if any)
bands in the position of the lost allele suggesting only very
mild infiltration of normal cells. Since the same DNA was
used in the SSCP analysis we feel confident that the presence
of normal cells in the tumour is not masking any mutation in
the tumour cells. In fact, we have clearly shown that muta-
tions are detected easily by SSCP when only 50% of the
DNA carries the abnormality (Baird et al., 1992a).
Major structural rearrangements of WT1 have been shown
in less than 10% of Wilms' tumours (Cowell et al., 1991)
and, using Southern blotting techniques, all of these were
shown to be deletions (Brown et al., 1992; Cowell et al.,
1991; Huff et al., 1991; Tadokoro et al., 1992; Ton et al.,
1991). More subtle mutations, however, would not be detect-
ed using this technique. Mutations have been reported, how-
ever, in a variety of patients with particular phenotypic
features. Thus, patients with DDS, who are also predisposed
to Wilms' tumorigenesis (Jadresic et al., 1991), carry constitu-
tional mutations in WT1 (Baird et al., 1992b; Pelletier et al.,
1991a,b). All of these mutations are found in the zinc finger
region ofWT1, with the one exception from our series, where
a mutation in exon 6 was observed in GOS 217. This bias
towards the zinc finger region was also observed for larger
intragenic deletions (Brown et al., 1992; Cowell et al., 1991;
Tadokoro et al., 1992) as well as in patients with constitu-
tional lip13 deletions (Baird et al., 1992b; Brown et al.,
1992). In these patients one copy of the WT1 gene is consti-
tutionally deleted so only one copy remains and must be
mutant if WT1 is important in tumorigenesis in these cases.
Although we were confident that SSCP would identify most
mutations, because of the high frequency with which muta-
tions have been observed in the zinc finger regions of WT1
we decided to sequence exons 7-10 in the five tumours
showing LOH anyway. All were shown to have the normal
sequence as published by Haber et al. (1991) which confirmed
our SSCP analysis. In two previous analyses of patients we
were also unable to show abnormalities using SSCP. Thus, in
one lIp-deletion patient, with bilateral tumours (Baird et al.,
1992b), and a patient with typical DDS (Baird et al., 1992a),
despite observing normal banding profiles for all exons using
SSCP analysis, we also analysed the genomic WT1 sequence
and were still unable to find any mutations. Although we
have not formally proved the absence of mutations in exons
1-6 by sequencing we are confident that the high sensitivity
of the SSCP technique in our hands makes this a remote
possibility and we did not consider it necessary to sequence
these exons from those tumours showing LOH for lIp13. It
is remotely possible that all of the five tumours carry muta-
tions in the, as yet, unsequenced parts of WTI upstream of
the promoter regions or the 3' untranslated region but, in
light of the perferential location of WT1 mutations already
reported we consider it unlikely that this would be the case in
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all of these tumours. Although unlikely, another possiblity is
that promoter mutations exist in these tumours which pre-
vent normal transcription. We have previously shown that
PCR analysis of RNA transcripts from tumours is not quan-
titative (Baird et al., 1992b), due to the infiltration of con-
taminating normal cells, which also produce WTI transcripts.
This makes it impossible to distinguish between RNA trans-
cripts derived from tumour or normal cells.
Taken together our results suggest that allele loss on 1 lp is
not always associated with WT1 mutation as might have
been expected from the general LOH dogma. This suggestion
implies that other recessive genes on lIp are being revealed
by LOH. All five tumours in which we failed to find muta-
tions in WT1 also showed LOH in the lIpl5 region and it
may be that the LOH event in these tumours exposes a
recessive oncogene in that part of the chromosome. Since
WTI does not appear to be involved in this process, except
in some cases of tumours from DDS patients, it is possible
that other genes in llpl5 are more important in tumori-
genesis as we have argued previously (Baird et al., 1992a;
Cowell et al., 1991). On this point, in tumour GOS 66,
although the region of LOH extends beyond lp13 it does
not extend as far as the HRAS location in distal llpl5
(Wadey et al., 1990). This tumour, therefore, defines the
distal limit to the region which possibly contains the other
important gene, between INS and HRAS. Clearly, the precise
mechanism involved in Wilms' tumorigenesis in these
tumours will have to await the cloning of the lp15 gene(s)
before this issue can be fully resolved.
This work was supported in part by the Child Health Research
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